Insights
Search Results
Client Highlights
3.03.26
Wilson Sonsini Advises Versori on Acquisition by Avalara
On February 27, 2026, Avalara, the leading provider of cloud-based tax compliance automation software, announced that it acquired Versori Group, an integration platform company specializing in automated connector development powered by agentic AI. Wilson Sonsini Goodrich & Rosati advised Versori on the transaction.
Client Highlights
2.25.26
Wilson Sonsini Advises SambaNova on $350 Million Series E Financing
On February 24, 2026, SambaNova, a leader in next‑generation AI infrastructure, announced that it has raised more than $350 million in investment from new and existing investors. The oversubscribed Series E round was led by Vista Equity Partners and Cambium Capital, with strong participation from Intel Capital. Wilson Sonsini Goodrich & Rosati advised SambaNova on the transaction.
Client Highlights
11.05.25
Firm Advises Frontline Wildfire Defense on $48 Million Series A Funding Round
On October 28, 2025, Frontline Wildfire Defense, the leading wildfire defense solution for homes, businesses, and communities, announced it has closed a $48 million Series A round led by Norwest to scale its proven wildfire defense systems across fire-prone states. Wilson Sonsini Goodrich & Rosati advised Frontline Wildfire Defense on the transaction.
Alerts
10.30.25
SEC Chairman Addresses Potential Reforms Relating to Shareholder Proposals and Shareholder Litigation
On October 9, 2025, Chairman Paul S. Atkins of the U.S. Securities and Exchange Commission (SEC) gave a much-publicized keynote address at the University of Delaware’s John L. Weinberg Center for Corporate Governance.1 In the speech, Chairman Atkins generally expressed concern over the costs and difficulties facing public companies in the U.S. and identified several possible areas of reform, including with respect to practices surrounding shareholder proposals at shareholder meetings and the current shareholder litigation environment. These remarks follow a Policy Statement issued by the SEC on September 17, 2025, signaling that the use of mandatory arbitration provisions in a company’s governing documents to address shareholder litigation would not impact the SEC’s decisions to declare registration statements effective.2 Public companies, and those companies considering going public, will want to monitor these developments closely.
Client Highlights
9.25.25
Wilson Sonsini Advises LALO Tequila on Acquisition by Tito’s
On September 23, 2025, Tito's Handmade Vodka, the brand behind Texas' first legal distillery and the award-winning vodka, announced it has entered into a definitive agreement to acquire the majority stake in LALO Tequila, one of the fastest-growing tequila brands in the United States. Wilson Sonsini Goodrich & Rosati advised LALO on the transaction.
Client Highlights
7.25.25
Wilson Sonsini Advises Revival on Strategic Partnership with Olympus
On July 25, 2025, Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships in MedTech, announced a strategic partnership with Olympus Corporation (Olympus), a global healthcare leader committed to making people’s lives healthier, safer, and more fulfilling through advanced medical technologies and solutions. The partnership is aimed at harnessing external innovation to accelerate development and market entry for an endoluminal robotics platform initially targeting gastrointestinal (GI) treatments. Wilson Sonsini Goodrich & Rosati advised Revival on the transaction and on fund matters related to the transaction.
Client Highlights
12.20.24
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio
On December 19, 2024, Aadi Bioscience announced that it had entered into an agreement to sell its commercial drug product FYARRO® to KAKEN Pharmaceutical for $100 million, an agreement to sell and issue $100 million of equity in a PIPE financing, and an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, and Hangzhou DAC, a global leader in ADC innovation.
Client Highlights
5.29.24
Wilson Sonsini Advises FTAI Aviation's Special Committee on Internalization
On May 28, 2024, FTAI Aviation (FTAI), an owner and operator of commercial jet engines, announced that it has entered into definitive agreements providing for the internalization of the company’s management operations. Pursuant to the internalization agreement, FTAI and FIG LLC terminated the Management and Advisory Agreement dated July 31, 2022, and the Services and Profit Sharing Agreement dated November 10, 2022, effective as of May 28, 2024. FTAI's board of directors established a special committee of independent and disinterested directors to negotiate and approve the terms of the internalization. Wilson Sonsini Goodrich & Rosati advised the special committee in connection with the internalization.
Client Highlights
12.03.23
Wilson Sonsini Advises Hawaiian Airlines on $1.9 Billion Acquisition by Alaska Airlines
On December 3, 2023, Alaska Airlines and Hawaiian Airlines announced that they had entered into a definitive agreement pursuant to which Alaska Airlines will acquire the holding company of Hawaiian Airlines for $18.00 per share in cash, for a transaction value of approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Hawaiian Airlines on the transaction.
Alerts
9.02.22
California Adopts Ratification and Verification Statute for Corporations
Throughout the life cycle of a company, and especially during the leaner early start-up stages, corporate actions that are defective due to failures to obtain the correct board or shareholder votes, errors in the approval process, or failures to make filings with the applicable Secretary of State are not uncommon. These defects, while detrimental on their own, can also call into question the validity of some or all other board and shareholder approvals, and thus substantive corporate transactions down the line. For example, if the holders of invalidly issued stock of a company later participate in the approval of a sale of the company, that later sale transaction may also be invalid because it was not approved by the requisite vote of valid shareholders. To compound this, common law ratification (e.g., approval of challenged or defective board or shareholder action by a later vote of the board and/or shareholders) is not always available for such defective actions, and even when it is available, it is not clear that the ratification can "relate back" to the date of the initial defective act so that acts subsequent to the arguably now remedied act would themselves no longer be defective.
Client Highlights
1.12.22
Wilson Sonsini Advises project44 on $240 Million Investment and Related Transactions
On January 11, 2022, project44, a leading supply chain visibility platform, announced it completed a $240 million financing. A syndicate led by Thoma Bravo, TPG, and Goldman Sachs Asset Management with participation from Emergence Capital, Insight Partners, Chicago Ventures, Generation Investment Management, Sapphire, and Sozo Ventures acquired equity interests resulting in a pre-money valuation of $2.2 billion. Sixth Street has committed to make available additional funding in support of the company’s strategic acquisition program and product development activities. In addition, the investor group also is in the process of purchasing up to $180 million from an insider group of existing stockholders. The company plans to spend its proceeds on expanding its network, strategic acquisitions, and hiring product and engineering staff in nations including Japan, Brazil, and China.
Client Highlights
12.09.21
Wilson Sonsini Represents HashiCorp in Initial Public Offering
On December 8, 2021, HashiCorp®, a leader in multi-cloud infrastructure automation software, announced the pricing of its initial public offering of 15,300,000 shares of its Class A common stock at a public offering price of $80.00 per share. All of the shares are being offered by HashiCorp. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by HashiCorp, are expected to be $1.22 billion. The shares began trading on the Nasdaq Global Select Market on December 9, 2021, under the ticker symbol “HCP.” The offering is expected to close on December 13, 2021, subject to the satisfaction of customary closing conditions. In addition, HashiCorp has granted the underwriters a 30-day option to purchase up to an additional 2,295,000 shares of Class A common stock at the initial public offering price, less the underwriting discounts and commissions.